(S)-Azepane-1-carboxylic acid (1-{4-[(4-amino-phenyl)-(3-methyl-butyl)-amino]-piperidine-1-carbonyl}-3-methyl-butyl)-amide | 220737-77-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-Azepane-1-carboxylic acid (1-{4-[(4-amino-phenyl)-(3-methyl-butyl)-amino]-piperidine-1-carbonyl}-3-methyl-butyl)-amide
• 英文别名: Azepane-1-carboxylic acid (1-{4-[(4-amino-phenyl)-(3-methyl-butyl)-amino]-piperidine-1-carbonyl}-3-methyl-butyl)-amide；N-[(2S)-1-[4-[4-amino-N-(3-methylbutyl)anilino]piperidin-1-yl]-4-methyl-1-oxopentan-2-yl]azepane-1-carboxamide
• CAS: 220737-77-9
• 化学式: C₂₉H₄₉N₅O₂
• 分子量: 499.74
• InChiKey: VFKMZDWOAHCUAR-MHZLTWQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.72
• 拓扑面积：
  81.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-羟基丁醛 、 (S)-Azepane-1-carboxylic acid (1-{4-[(4-amino-phenyl)-(3-methyl-butyl)-amino]-piperidine-1-carbonyl}-3-methyl-butyl)-amide 在 三乙酰氧基硼氢化钠 作用下， 以 二氯甲烷 为溶剂， 生成 Azepane-1-carboxylic acid ((S)-1-{4-[[4-(3-hydroxy-butylamino)-phenyl]-(3-methyl-butyl)-amino]-piperidine-1-carbonyl}-3-methyl-butyl)-amide
  参考文献：
  名称：

  Structure-activity relationship at the proximal phenyl group in a series of non-peptidyl N-type calcium channel antagonists

  摘要：

  Selective N-Type Voltage Sensitive Calcium Channel (VSCC) antagonists have shown utility in several models of pain and ischemia. We report the structure-activity relationship at the proximal phenyl group in a series of non-peptidyl VSCC blockers, (C) 1999 Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00405-9
• 作为产物：
  描述：

  n-(4-氨基苯基)氨基甲酸苄酯 在 palladium on activated charcoal 氢气 、 三乙酰氧基硼氢化钠 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (S)-Azepane-1-carboxylic acid (1-{4-[(4-amino-phenyl)-(3-methyl-butyl)-amino]-piperidine-1-carbonyl}-3-methyl-butyl)-amide
  参考文献：
  名称：

  Structure-activity relationship at the proximal phenyl group in a series of non-peptidyl N-type calcium channel antagonists

  摘要：

  Selective N-Type Voltage Sensitive Calcium Channel (VSCC) antagonists have shown utility in several models of pain and ischemia. We report the structure-activity relationship at the proximal phenyl group in a series of non-peptidyl VSCC blockers, (C) 1999 Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(99)00405-9

文献信息

• Aniline derivatives as calcium channel blockers
  申请人：Warner-Lambert Company

  公开号：US06251918B1

  公开（公告）日：2001-06-26

  The present invention provides compounds that block calcium channels having formula (I). The present invention also provides methods of using the compounds of formula (I) to treat stroke, cerebral ischemia, head trauma, or epilepsy and to pharmaceutical compositions that contain the compounds of formula (I).

  本发明提供了一种阻断钙通道的化合物，其化学式为(I)。本发明还提供了使用化合物(I)治疗中风、脑缺血、头部创伤或癫痫的方法，以及含有化合物(I)的药物组合物。
• Calcium channel blockers
  申请人：——

  公开号：US20010023249A1

  公开（公告）日：2001-09-20

  The present invention provides compounds that block calcium channels having the Formula I shown below. 1 The present invention also provides methods of using the compounds of Formula I to treat stroke, cerebral ischemia, head trauma, or epilepsy and to pharmaceutical compositions that contain the compounds of Formula I.

  本发明提供了具有下面式子I的阻断钙通道的化合物。同时，本发明还提供了使用式子I的化合物治疗中风、脑缺血、头部创伤或癫痫的方法，以及含有式子I的制药组合物。
• Structure-activity relationship at the proximal phenyl group in a series of non-peptidyl N-type calcium channel antagonists
  作者：Todd R. Ryder、Lain-Yen Hu、Michael F. Rafferty、Susan M. Lotarski、David M. Rock、Sally J. Stoehr、Charles P. Taylor、Mark L. Weber、George P. Miljanich、Elizabeth Millerman、Balazs G. Szoke

  DOI：10.1016/s0960-894x(99)00405-9

  日期：1999.8

  Selective N-Type Voltage Sensitive Calcium Channel (VSCC) antagonists have shown utility in several models of pain and ischemia. We report the structure-activity relationship at the proximal phenyl group in a series of non-peptidyl VSCC blockers, (C) 1999 Published by Elsevier Science Ltd. All rights reserved.